Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-07-29FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Clozapine from Mylan Pharmaceuticals Inc.
-
FDA approval · 2021-07-29FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
The FDA approved a supplemental application for Versacloz, a brand of clozapine, submitted by TruPharma LLC.
-
FDA approval · 2021-07-29FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Clozapine submitted by Mylan Pharmaceuticals Inc., authorizing a generic Clozapine product.
-
FDA approval · 2021-07-29FDA Approved: CLOZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for CLOZAPINE submitted by Teva Pharmaceuticals USA, Inc.
-
FDA approval · 2021-07-29FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for Clozaril (clozapine) submitted by HLS Therapeutics USA, Inc., typically to update labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: Sulforaphane to Reduce Symptoms of Schizophrenia [Phase 2]
Phase 2 clinical trial evaluating sulforaphane for reducing symptoms in schizophrenia and schizoaffective disorder has completed with result…
-
FDA approval · 2021-07-26FDA Approved: HALOPERIDOL DECANOATE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved haloperidol decanoate under an original ANDA from Meitheal Pharmaceuticals as a long-acting injectable antipsychotic indicated …
-
CLINICAL_TRIALS trial_result · 2021-07-21Clinical Trial Update: A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia [Phase 3]
Phase 3 long-term safety and tolerability study of ALKS 3831 in adults with schizophrenia completed; results posted.
-
FDA label_change · 2021-07-19FDA Approved: ASENAPINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for asenapine from Alembic Pharmaceuticals Limited, resulting in updated labeling for the drug.
-
FDA approval · 2021-07-19FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for ziprasidone hydrochloride from Apotex Corp., enabling the marketing of a generic version of the …
-
FDA approval · 2021-07-19FDA Approved: QUETIAPINE EXTENDED-RELEASE — Supplemental Application (AlignScience Pharma Inc.)
FDA approved AlignScience Pharma Inc.'s supplemental application for quetiapine extended-release, enabling its marketing as a generic produc…
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Improving Visual Attention in Schizophrenia [NA]
Completed clinical trial investigating improving visual attention in schizophrenia and schizoaffective disorder; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia [NA]
A completed clinical trial study addressing negative symptoms and community engagement in veterans with schizophrenia and serious mental ill…
-
CLINICAL_TRIALS trial_result · 2021-07-08Clinical Trial Update: Remediation of Auditory Recognition in Schizophrenia With tDCS [NA]
Completed clinical trial investigating remediation of auditory recognition in schizophrenia using transcranial Direct Current Stimulation (t…
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone [Phase 4]
Phase 4 trial evaluating safety, tolerability, pharmacokinetics, and efficacy of 180 mg subcutaneous risperidone following 6 mg oral risperi…
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia [Phase 2]
Phase 2 study evaluating ABT-126 for cognitive deficits in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2021-07-07Clinical Trial Update: A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia [Phase 2]
Phase 2 trial evaluating ABT-126 for cognitive deficits in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia [Phase 4]
Phase 4 clinical trial evaluating weekly exenatide injections as an adjunctive treatment for schizophrenia and schizoaffective disorder.
-
CLINICAL_TRIALS withdrawal · 2021-06-03Clinical Trial Update: SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia [Phase 3]
Phase 3 study SPD489 as adjunctive treatment for negative symptoms of schizophrenia was withdrawn.
-
FDA approval · 2021-06-02FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Original Application (Sandoz, Inc.)
FDA approved chlorpromazine hydrochloride as a generic drug through an original ANDA submitted by Sandoz, Inc.
-
FDA approval · 2021-05-28FDA Approved: LYBALVI — Original Application (Alkermes, Inc.)
FDA approved LYBALVI (olanzapine and samidorphan L-malate) from Alkermes as an original drug application. It is indicated for the treatment …
-
FDA approval · 2021-05-27FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Zydus Pharmaceuticals (USA) Inc.)
The FDA approved the original application for Fluphenazine hydrochloride from Zydus Pharmaceuticals (USA) Inc., enabling marketing as a gene…
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: Treating Smokers With Mental Illness [Phase 2]
Phase 2 clinical trial assessing treatments for smoking cessation in individuals with mental illness; study completed with posted results in…
-
CLINICAL_TRIALS trial_result · 2021-05-24Clinical Trial Update: Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients [Phase 4]
Phase 4 trial update on adjunctive use of flupentixol (Fute) in patients with schizophrenia treated with multi-acting receptor-targeted anti…
-
CLINICAL_TRIALS trial_result · 2021-05-20Clinical Trial Update: Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia [Phase 2]
A Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of Evenamide for chronic schizophrenia has completed.